Background: Larval stage of Echinococcus granulosus is the main cause of the hydatid cyst. Surgery, which is both aggressive and high-risk, is the most common treatment for this type of cyst. Some medicines, such as mebendazole, are also used as a complementary approach to preventing the recurrence of hydatid cysts. Objectives: Considering the approved antiparasitic effects of sodium valproate (VPA) on some parasites, this research intended to examine the potential of VPA against protoscolices and hydatid walls. Methods: Liver hydatid cysts caused by E. granulosus were collected from a slaughterhouse. Protoscolices and hydatid cysts were exposed to RPMI and dimethyl sulfoxide (DMSO) media (control groups) or different concentrations of VPA and mebendazole in vitro. The viability of protoscolices was evaluated via light microscopy. Also, tissue changes and expression of apoptotic caspase-3 were examined in hydatid cyst walls (HCWs) using histological and immunohistochemical methods, respectively. Results: The mortality rates of VPA-treated and mebendazole-treated protoscolices were dose- and time-dependent. There was a significant difference between the intervention and control groups (P < 0.05). Tissue changes and apoptosis were observed in VPA-treated and mebendazole-treated HCWs. Conclusions: Valproate and mebendazole had significant effects on protoscolices and HCWs, although VPA exerted its effects more rapidly. It seems that VPA can be a new promising protoscolicidal agent and anti-hydatid medicine.
{"title":"Anti-hydatidosis Potential of Sodium Valproate: Evaluating New Therapeutic Potential for Sodium Valproate","authors":"M. Rezaie, R. Rahimi, Z. Eslamirad","doi":"10.5812/archcid-121871","DOIUrl":"https://doi.org/10.5812/archcid-121871","url":null,"abstract":"Background: Larval stage of Echinococcus granulosus is the main cause of the hydatid cyst. Surgery, which is both aggressive and high-risk, is the most common treatment for this type of cyst. Some medicines, such as mebendazole, are also used as a complementary approach to preventing the recurrence of hydatid cysts. Objectives: Considering the approved antiparasitic effects of sodium valproate (VPA) on some parasites, this research intended to examine the potential of VPA against protoscolices and hydatid walls. Methods: Liver hydatid cysts caused by E. granulosus were collected from a slaughterhouse. Protoscolices and hydatid cysts were exposed to RPMI and dimethyl sulfoxide (DMSO) media (control groups) or different concentrations of VPA and mebendazole in vitro. The viability of protoscolices was evaluated via light microscopy. Also, tissue changes and expression of apoptotic caspase-3 were examined in hydatid cyst walls (HCWs) using histological and immunohistochemical methods, respectively. Results: The mortality rates of VPA-treated and mebendazole-treated protoscolices were dose- and time-dependent. There was a significant difference between the intervention and control groups (P < 0.05). Tissue changes and apoptosis were observed in VPA-treated and mebendazole-treated HCWs. Conclusions: Valproate and mebendazole had significant effects on protoscolices and HCWs, although VPA exerted its effects more rapidly. It seems that VPA can be a new promising protoscolicidal agent and anti-hydatid medicine.","PeriodicalId":51793,"journal":{"name":"Archives of Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2022-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47872939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Amirmasoud Kazemzadeh Houjaghan, S. Abdi, M. Bahreini
Introduction: The new pandemic of coronavirus disease 2019 (COVID-19) has evolved certain neurologic syndromes as a presentation of this disease that should be integrated into the whole disease process. Case Presentations: We present cases of neurologic involvement in adult patients with documented bronchopulmonary COVID-19. Certain signs and symptoms are introduced, including new onset seizures, ischemic stroke, and altered mental status in otherwise minimal clinical signs and symptoms of COVID-19. Conclusions: Many neurologic presentations are diagnosed in resolving COVID respiratory infections or in an otherwise asymptomatic individual.
{"title":"Neurologic Presentations of COVID-19: A Case Series","authors":"Amirmasoud Kazemzadeh Houjaghan, S. Abdi, M. Bahreini","doi":"10.5812/archcid-116401","DOIUrl":"https://doi.org/10.5812/archcid-116401","url":null,"abstract":"Introduction: The new pandemic of coronavirus disease 2019 (COVID-19) has evolved certain neurologic syndromes as a presentation of this disease that should be integrated into the whole disease process. Case Presentations: We present cases of neurologic involvement in adult patients with documented bronchopulmonary COVID-19. Certain signs and symptoms are introduced, including new onset seizures, ischemic stroke, and altered mental status in otherwise minimal clinical signs and symptoms of COVID-19. Conclusions: Many neurologic presentations are diagnosed in resolving COVID respiratory infections or in an otherwise asymptomatic individual.","PeriodicalId":51793,"journal":{"name":"Archives of Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2022-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45686782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Shortage of Coronavirus RT-PCR Kits May Increase the Spread of Infection in Kurdistan Region of Iraq","authors":"N. Hussein, I. Naqid","doi":"10.5812/archcid-102896","DOIUrl":"https://doi.org/10.5812/archcid-102896","url":null,"abstract":"<jats:p />","PeriodicalId":51793,"journal":{"name":"Archives of Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2022-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47080521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Abuova, N. Pshenichnaya, L. Karan, F. Berdaliyeva, D. Aliyev, D. Sadyhova, T. Polukchi, S. Nurmagambet
Background: The Turkestan region of Kazakhstan is the natural focus of the Congo-Crimean hemorrhagic fever (CCHF). Every year, some of the patients treated in hospitals are not included in official statistics and remain in the group of possible cases of CCHF. Objectives: This study aimed to verify the genotypes of the CCHF virus (CCHFV) in the Turkestan region and Shymkent City. Methods: Twelve blood samples from patients with CCHF were studied, the diagnosis of which was verified on the basis of positive specific immunoglobulins IgM to the virus. To isolate viral RNA, we used a special MAGNO-sorb kit. To detect RNA, CCHFV was used with a set of Amplisens CCHFV-FL by real-time polymerase chain reaction (PCR) using a Rotor-Gene Q device. For the reverse transcription reaction, we used a set of Reverta-L. Results: The study of the genome sequence of CСHFV from GenBank demonstrated that isolates from the Turkestan region belonged to genetic groups Asia-1 and Asia-2. Conclusions: For the first time in Kazakhstan’s history, a phylogenetic analysis of RNA sequences of viruses from patients with CCHF was performed in the Turkestan region, as a result of which genetic groups Asia-1, reassortant Asia-1, and Asia-2 were established
{"title":"Genotypes of the Congo-Crimean Hemorrhagic Fever Virus Occurring in the Turkestan Region","authors":"G. Abuova, N. Pshenichnaya, L. Karan, F. Berdaliyeva, D. Aliyev, D. Sadyhova, T. Polukchi, S. Nurmagambet","doi":"10.5812/archcid-129126","DOIUrl":"https://doi.org/10.5812/archcid-129126","url":null,"abstract":"Background: The Turkestan region of Kazakhstan is the natural focus of the Congo-Crimean hemorrhagic fever (CCHF). Every year, some of the patients treated in hospitals are not included in official statistics and remain in the group of possible cases of CCHF. Objectives: This study aimed to verify the genotypes of the CCHF virus (CCHFV) in the Turkestan region and Shymkent City. Methods: Twelve blood samples from patients with CCHF were studied, the diagnosis of which was verified on the basis of positive specific immunoglobulins IgM to the virus. To isolate viral RNA, we used a special MAGNO-sorb kit. To detect RNA, CCHFV was used with a set of Amplisens CCHFV-FL by real-time polymerase chain reaction (PCR) using a Rotor-Gene Q device. For the reverse transcription reaction, we used a set of Reverta-L. Results: The study of the genome sequence of CСHFV from GenBank demonstrated that isolates from the Turkestan region belonged to genetic groups Asia-1 and Asia-2. Conclusions: For the first time in Kazakhstan’s history, a phylogenetic analysis of RNA sequences of viruses from patients with CCHF was performed in the Turkestan region, as a result of which genetic groups Asia-1, reassortant Asia-1, and Asia-2 were established","PeriodicalId":51793,"journal":{"name":"Archives of Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2022-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45799129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Karimi, Z. Sedaghat, Vahid Jahanfekr, M. Bagheri, Athena Sharifi-Razavi
Background: Although COVID-19 preferentially affects the respiratory system, it has been demonstrated that coronaviruses frequently invade the nervous system. Objectives: We aimed to report the frequency and type of neurological manifestations in hospitalized patients with COVID-19. Methods: This is a retrospective, prospective observational cohort study. Data were collected from April to July 2020 at Bu-Ali Sina University Hospital, Sari, Iran. Demographic data and clinical symptoms were recorded at the onset of the disease. Neurological manifestations were recorded into 5 categories: nonspecific central nervous system (CNS) manifestations, acute cerebrovascular disease (CVD), meningitis/encephalitis, peripheral nervous system manifestations, and inflammatory disorders (myelitis and acute disseminated encephalomyelitis). Results: A total of 420 patients were admitted to the hospital with confirmed SARS-CoV-2 infection. Of the 420 patients hospitalized with COVID-19, 282 (67%) showed some form of neurological symptoms, of whom 48.33% had nonspecific neurological symptoms. Further, 35 (8.3%) patients had acute CVD, 2 patients had encephalitis (the RNA of SARS-CoV-2 was detected in cerebrospinal fluid (CSF), 1 patient had myelitis, and 83 (19.76%) patients had peripheral nervous system manifestations. Conclusions: Neurologic symptoms (from mild symptoms to life-threatening CNS disorders) are common in admitted patients with COVID-19. As a result of coagulation disorder in patients with COVID-19, some conditions (such as stroke) can be seen, even during recovery.
背景：尽管新冠肺炎优先影响呼吸系统，但已证明冠状病毒经常侵入神经系统。目的：我们旨在报告新冠肺炎住院患者神经系统表现的频率和类型。方法：这是一项回顾性、前瞻性的队列观察研究。数据收集于2020年4月至7月，地点为伊朗萨里的Bu Ali Sina大学医院。发病时记录人口统计学数据和临床症状。神经系统表现分为5类：非特异性中枢神经系统（CNS）表现、急性脑血管病（CVD）、脑膜炎/脑炎、外周神经系统表现和炎症性疾病（脊髓炎和急性播散性脑脊髓炎）。结果：共有420名确诊感染严重急性呼吸系统综合征冠状病毒2型的患者入院。在420名新冠肺炎住院患者中，282人（67%）表现出某种形式的神经系统症状，其中48.33%表现出非特异性神经系统症状。此外，35名（8.3%）患者患有急性CVD，2名患者患有脑炎（在脑脊液中检测到严重急性呼吸系统综合征冠状病毒2型的RNA），1名患者患有脊髓炎，83名（19.76%）患者有外周神经系统表现。结论：新冠肺炎住院患者常见神经系统症状（从轻微症状到危及生命的中枢神经系统疾病）。由于新冠肺炎患者的凝血障碍，即使在康复期间，也可以看到一些情况（如中风）。
{"title":"Neurological Manifestations of Hospitalized COVID-19-Infected Patients: A Single-Center Cohort Study","authors":"N. Karimi, Z. Sedaghat, Vahid Jahanfekr, M. Bagheri, Athena Sharifi-Razavi","doi":"10.5812/archcid-116117","DOIUrl":"https://doi.org/10.5812/archcid-116117","url":null,"abstract":"Background: Although COVID-19 preferentially affects the respiratory system, it has been demonstrated that coronaviruses frequently invade the nervous system. Objectives: We aimed to report the frequency and type of neurological manifestations in hospitalized patients with COVID-19. Methods: This is a retrospective, prospective observational cohort study. Data were collected from April to July 2020 at Bu-Ali Sina University Hospital, Sari, Iran. Demographic data and clinical symptoms were recorded at the onset of the disease. Neurological manifestations were recorded into 5 categories: nonspecific central nervous system (CNS) manifestations, acute cerebrovascular disease (CVD), meningitis/encephalitis, peripheral nervous system manifestations, and inflammatory disorders (myelitis and acute disseminated encephalomyelitis). Results: A total of 420 patients were admitted to the hospital with confirmed SARS-CoV-2 infection. Of the 420 patients hospitalized with COVID-19, 282 (67%) showed some form of neurological symptoms, of whom 48.33% had nonspecific neurological symptoms. Further, 35 (8.3%) patients had acute CVD, 2 patients had encephalitis (the RNA of SARS-CoV-2 was detected in cerebrospinal fluid (CSF), 1 patient had myelitis, and 83 (19.76%) patients had peripheral nervous system manifestations. Conclusions: Neurologic symptoms (from mild symptoms to life-threatening CNS disorders) are common in admitted patients with COVID-19. As a result of coagulation disorder in patients with COVID-19, some conditions (such as stroke) can be seen, even during recovery.","PeriodicalId":51793,"journal":{"name":"Archives of Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2022-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47956459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Susanto, H. Agustin, M. Taufik, M. Rahman, Moulid Hidayat
Background: Coronavirus disease 2019 (COVID-19) is a contagious infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) declared this infection a global pandemic in 2020. In addition, various methods have been developed to diagnose COVID-19 rapidly and accurately to reverse transcription-polymerase chain reaction (RT-PCR) as a gold standard method. One of these methods is the detection of volatile organic compounds (VOC) in exhaled breath. Objectives: The aim was to collect and investigate studies on the accuracy of VOC detection as a diagnostic method for COVID-19. Methods: A literature search was performed in five electronic databases, including PubMed, Cochrane Library, ProQuest, EBSCOhost, and Scopus, along with hand searching. The search was conducted in the titles and abstracts of articles using keywords and their equivalent terms, combined with the Boolean operators (OR and AND). The search results were then selected according to the inclusion and exclusion criteria and compatibility with the Population, Intervention, Control, and Outcomes (PICO) framework. Results: Based on the search results, two cross-sectional studies by Wintjens et al. and Ruszkiewicz et al. were selected, which were then critically appraised. Both studies showed good validity. Wintjens et al. reported 86% sensitivity and 54% specificity for their method, with a positive predictive value (PPV) and a negative predictive value (NPV) of 40% and 92%, respectively. Besides, Ruszkiewicz et al., who conducted a study in two different locations, reported 82.4% sensitivity and 75% specificity for their method in Edinburgh (UK), with PPV and NPV of 87.5% and 66.7%, respectively, while they reported 90% sensitivity and 80% specificity in Dortmund (Germany), with PPV and NPV of 45% and 97.8%, respectively. The accuracy of these three methods was 62%, 80%, and 82%, respectively. Conclusions: Detection of VOCs from exhaled breath can be a rapid, cost-effective, and simple method for diagnosing COVID-19. However, the accuracy of this method is still relatively low (62 - 82%) and inconsistent; therefore, it is only recommended for screening.
{"title":"Accuracy of Volatile Organic Compound (VOC) Detection in Exhaled Breath Compared to Reverse-transcriptase Polymerase Chain Reaction (RT-PCR) for Diagnosis of COVID-19: An Evidence-based Case Report","authors":"A. Susanto, H. Agustin, M. Taufik, M. Rahman, Moulid Hidayat","doi":"10.5812/archcid-119263","DOIUrl":"https://doi.org/10.5812/archcid-119263","url":null,"abstract":"Background: Coronavirus disease 2019 (COVID-19) is a contagious infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) declared this infection a global pandemic in 2020. In addition, various methods have been developed to diagnose COVID-19 rapidly and accurately to reverse transcription-polymerase chain reaction (RT-PCR) as a gold standard method. One of these methods is the detection of volatile organic compounds (VOC) in exhaled breath. Objectives: The aim was to collect and investigate studies on the accuracy of VOC detection as a diagnostic method for COVID-19. Methods: A literature search was performed in five electronic databases, including PubMed, Cochrane Library, ProQuest, EBSCOhost, and Scopus, along with hand searching. The search was conducted in the titles and abstracts of articles using keywords and their equivalent terms, combined with the Boolean operators (OR and AND). The search results were then selected according to the inclusion and exclusion criteria and compatibility with the Population, Intervention, Control, and Outcomes (PICO) framework. Results: Based on the search results, two cross-sectional studies by Wintjens et al. and Ruszkiewicz et al. were selected, which were then critically appraised. Both studies showed good validity. Wintjens et al. reported 86% sensitivity and 54% specificity for their method, with a positive predictive value (PPV) and a negative predictive value (NPV) of 40% and 92%, respectively. Besides, Ruszkiewicz et al., who conducted a study in two different locations, reported 82.4% sensitivity and 75% specificity for their method in Edinburgh (UK), with PPV and NPV of 87.5% and 66.7%, respectively, while they reported 90% sensitivity and 80% specificity in Dortmund (Germany), with PPV and NPV of 45% and 97.8%, respectively. The accuracy of these three methods was 62%, 80%, and 82%, respectively. Conclusions: Detection of VOCs from exhaled breath can be a rapid, cost-effective, and simple method for diagnosing COVID-19. However, the accuracy of this method is still relatively low (62 - 82%) and inconsistent; therefore, it is only recommended for screening.","PeriodicalId":51793,"journal":{"name":"Archives of Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2022-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45993867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Early and Severe Flu Season May Start After COVID-19","authors":"M. Mardani","doi":"10.5812/archcid-132840","DOIUrl":"https://doi.org/10.5812/archcid-132840","url":null,"abstract":"<jats:p />","PeriodicalId":51793,"journal":{"name":"Archives of Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2022-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47337138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Parastoo Ashouri, Jafar Mohammadshahi, V. Nikbin, H. Peeridogaheh, B. Mohammadi-ghalehbin, Siheila Refahi, Amir Teimourpour, M. Esmaelizad, Hafez Mirzaneghad, Roghayeh Teimourpour
Background: Acinetobacte is the leading cause of pneumonia and sepsis in the ICU ward. Accordingly, in the present study, the antibiotic susceptibility pattern, presence, and dissemination of different classes of integrons and fluoroquinolone resistance genes were investigated among A. baumannii isolates. Methods: In this descriptive, cross-sectional study, during a period of 24 months (2018-2020), 100 isolates of A. baumannii were isolated from different clinical specimens of patients admitted to the two teaching hospital in Ardabil province in the northwest of Iran. Kirby -Bauer disk diffusion, PCR, and sequencing methods were used for antimicrobial susceptibility testing and gene and mutation verification. Results: The resistance rates to all tested antibiotics were found to be between 78% and 100%. No isolate was resistant to polymyxin B. Multidrug-resistant (MDR) rate among tested clinical isolates was about 99%. The prevalence of class 1, 2, and 3 integrons was found to be 70%, 21%, and 0%, respectively. The aadA1 cassette gene was detected in all class 1 integron-carrying strains. Conclusions: High-level antibiotic resistance and a high prevalence of integrons were observed among these clinical isolates. Our findings highlighted the need for continuous monitoring of resistant isolates.
{"title":"Antimicrobial Resistance, Integron Carriage, and Fluoroquinolone Resistance Genes in Acinetobacte baumannii Isolates","authors":"Parastoo Ashouri, Jafar Mohammadshahi, V. Nikbin, H. Peeridogaheh, B. Mohammadi-ghalehbin, Siheila Refahi, Amir Teimourpour, M. Esmaelizad, Hafez Mirzaneghad, Roghayeh Teimourpour","doi":"10.5812/archcid-120590","DOIUrl":"https://doi.org/10.5812/archcid-120590","url":null,"abstract":"Background: Acinetobacte is the leading cause of pneumonia and sepsis in the ICU ward. Accordingly, in the present study, the antibiotic susceptibility pattern, presence, and dissemination of different classes of integrons and fluoroquinolone resistance genes were investigated among A. baumannii isolates. Methods: In this descriptive, cross-sectional study, during a period of 24 months (2018-2020), 100 isolates of A. baumannii were isolated from different clinical specimens of patients admitted to the two teaching hospital in Ardabil province in the northwest of Iran. Kirby -Bauer disk diffusion, PCR, and sequencing methods were used for antimicrobial susceptibility testing and gene and mutation verification. Results: The resistance rates to all tested antibiotics were found to be between 78% and 100%. No isolate was resistant to polymyxin B. Multidrug-resistant (MDR) rate among tested clinical isolates was about 99%. The prevalence of class 1, 2, and 3 integrons was found to be 70%, 21%, and 0%, respectively. The aadA1 cassette gene was detected in all class 1 integron-carrying strains. Conclusions: High-level antibiotic resistance and a high prevalence of integrons were observed among these clinical isolates. Our findings highlighted the need for continuous monitoring of resistant isolates.","PeriodicalId":51793,"journal":{"name":"Archives of Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2022-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42461057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: About a year after the start of the coronavirus disease 2019 (COVID-19) pandemic, the results of the studies conducted to investigate the effectiveness of interferon (INF) compounds in this disease were contradictory. Objectives: This study was carried out to examine the safety and efficacy of a treatment protocol containing INF-β-1b, hydroxychloroquine, and Kaletra (lopinavir/ritonavir) in patients with severe COVID-19. Methods: In this open-label, randomized controlled trial, severe cases of COVID-19 were included. Patients were eligible if they had epidemiological and radiological evidence compatible with COVID-19 or a positive polymerase chain reaction result and their disease was severe. They were randomly allocated into a control group that received the standard regimen (hydroxychloroquine and Kaletra) and an intervention group that received INF-β-1b treatment and the standard treatment regimen. Then, the two groups were compared in terms of in-hospital mortality, intubation, length of hospital stay, oxygen saturation, and lactate dehydrogenase before and after the intervention. Results: A total of 91 cases of severe COVID-19 were enrolled for analysis [intervention (n = 47) and control (n = 44)]. The length of hospital stay in the intervention group was significantly longer than in the control group (13.21 ± 6.88 vs. 10.52 ± 5.77 days; P = 0.047). The mortality rate did not significantly differ between the intervention and control groups (19.15% and 13.64%, respectively; P = 0.509). The intubation rate did not significantly differ between the intervention and control groups (12.76% and 11.36%, respectively; P = 0.838). Conclusions: The use of INF-β-1b-containing treatment regimens does not reduce mortality and intubation rates among patients with severe COVID-19. Furthermore, it might even increase the severity of the disease and the length of hospital stay for some patients; therefore, it is not recommended to use INF-β-1b in severe cases of COVID-19.
{"title":"Safety and Efficacy of Interferon β-1b in the Treatment of Severe COVID-19 Patients: An Open-Label Randomized Controlled Trial","authors":"Javad Moazen, Leila Masoudiyekta, A. Kassani, Seifollah Mohseni, Nastaran Mirsamiyazdi, Mahnaz Nosratabadi, Shahzad Mehranfard, hojat Rezaei-Bayatiyani7","doi":"10.5812/archcid-120066","DOIUrl":"https://doi.org/10.5812/archcid-120066","url":null,"abstract":"Background: About a year after the start of the coronavirus disease 2019 (COVID-19) pandemic, the results of the studies conducted to investigate the effectiveness of interferon (INF) compounds in this disease were contradictory. Objectives: This study was carried out to examine the safety and efficacy of a treatment protocol containing INF-β-1b, hydroxychloroquine, and Kaletra (lopinavir/ritonavir) in patients with severe COVID-19. Methods: In this open-label, randomized controlled trial, severe cases of COVID-19 were included. Patients were eligible if they had epidemiological and radiological evidence compatible with COVID-19 or a positive polymerase chain reaction result and their disease was severe. They were randomly allocated into a control group that received the standard regimen (hydroxychloroquine and Kaletra) and an intervention group that received INF-β-1b treatment and the standard treatment regimen. Then, the two groups were compared in terms of in-hospital mortality, intubation, length of hospital stay, oxygen saturation, and lactate dehydrogenase before and after the intervention. Results: A total of 91 cases of severe COVID-19 were enrolled for analysis [intervention (n = 47) and control (n = 44)]. The length of hospital stay in the intervention group was significantly longer than in the control group (13.21 ± 6.88 vs. 10.52 ± 5.77 days; P = 0.047). The mortality rate did not significantly differ between the intervention and control groups (19.15% and 13.64%, respectively; P = 0.509). The intubation rate did not significantly differ between the intervention and control groups (12.76% and 11.36%, respectively; P = 0.838). Conclusions: The use of INF-β-1b-containing treatment regimens does not reduce mortality and intubation rates among patients with severe COVID-19. Furthermore, it might even increase the severity of the disease and the length of hospital stay for some patients; therefore, it is not recommended to use INF-β-1b in severe cases of COVID-19.","PeriodicalId":51793,"journal":{"name":"Archives of Clinical Infectious Diseases","volume":"1248 ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41279016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Maghbooli, A. Mirzaei, Zahra Jourahmad, H. Mirshahabi, Nazanin Azizi
Background: Herpes simplex virus (HSV) is a neurotropic DNA virus with a high prevalence. Following primary infection, HSV remains dormant in the neural ganglia. Secondary infection can emerge after the reactivation of latent infection, presenting as neurological manifestations. Previous studies have demonstrated the relationship between HSV reactivation and selective involvement of cranial nerves. Depending on the affected nerve, cranial mononeuropathies can present with symptoms, including diplopia, blurred vision, vertigo, unilateral facial palsy, speech impairment, swallowing difficulties, and hoarseness. Objectives: This study used a serological assay to compare HSV reactivation frequency between patients with recent idiopathic cranial mononeuropathies and normal individuals. Methods: Plasma samples from 35 idiopathic cranial mononeuropathy cases (57.2% women, mean age 58.37 years) and 35 age and sex-matched healthy controls were analyzed for anti-HSV immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies by enzyme-linked immunosorbent assay (ELISA). Results: Anti-HSV IgG antibody was positive in 91.4% of patients and 88.6% of controls. The mean serum anti-HSV IgG antibody level was significantly higher in patients (146.78 ± 60 RU/mL) than in the controls (130.61 ± 52.99 RU/mL) (P-value = 0.037). Anti-HSV IgM antibody was positive in 37.1% of patients and 14.3% of controls (P = 0.042). Conclusions: The frequency of HSV reactivation was significantly higher in patients with acute idiopathic cranial mononeuropathy than in the healthy controls, indicating the possible role of HSV as an etiology of cranial mononeuropathy.
{"title":"Comparison of Herpes Simplex Virus Reactivation Frequency in Acute Idiopathic Cranial Mononeuropathy and Normal Population by Serological Assay","authors":"M. Maghbooli, A. Mirzaei, Zahra Jourahmad, H. Mirshahabi, Nazanin Azizi","doi":"10.5812/archcid-126325","DOIUrl":"https://doi.org/10.5812/archcid-126325","url":null,"abstract":"Background: Herpes simplex virus (HSV) is a neurotropic DNA virus with a high prevalence. Following primary infection, HSV remains dormant in the neural ganglia. Secondary infection can emerge after the reactivation of latent infection, presenting as neurological manifestations. Previous studies have demonstrated the relationship between HSV reactivation and selective involvement of cranial nerves. Depending on the affected nerve, cranial mononeuropathies can present with symptoms, including diplopia, blurred vision, vertigo, unilateral facial palsy, speech impairment, swallowing difficulties, and hoarseness. Objectives: This study used a serological assay to compare HSV reactivation frequency between patients with recent idiopathic cranial mononeuropathies and normal individuals. Methods: Plasma samples from 35 idiopathic cranial mononeuropathy cases (57.2% women, mean age 58.37 years) and 35 age and sex-matched healthy controls were analyzed for anti-HSV immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies by enzyme-linked immunosorbent assay (ELISA). Results: Anti-HSV IgG antibody was positive in 91.4% of patients and 88.6% of controls. The mean serum anti-HSV IgG antibody level was significantly higher in patients (146.78 ± 60 RU/mL) than in the controls (130.61 ± 52.99 RU/mL) (P-value = 0.037). Anti-HSV IgM antibody was positive in 37.1% of patients and 14.3% of controls (P = 0.042). Conclusions: The frequency of HSV reactivation was significantly higher in patients with acute idiopathic cranial mononeuropathy than in the healthy controls, indicating the possible role of HSV as an etiology of cranial mononeuropathy.","PeriodicalId":51793,"journal":{"name":"Archives of Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2022-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44098639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：